Antisynthetase Syndrome Overview

Save information for later
Sign Up

Learn About Antisynthetase Syndrome

What is the definition of Antisynthetase Syndrome?
Antisynthetase syndrome is a chronic autoimmune condition that affects the muscles and various other parts of the body. The signs and symptoms can vary but may include muscle inflammation (myositis), polyarthritis (inflammation of many joints), interstitial lung disease, thickening and cracking of the hands, and Raynaud phenomenon. The exact underlying cause is unknown; however, the production of autoantibodies (antibodies that attack normal cells) that attack certain enzymes in the body called 'aminoacyl-tRNA synthetases' appears to be linked to the cause of the syndrome. These autoantibodies may arise after viral infections, or patients may have a genetic predisposition.
What are the alternative names for Antisynthetase Syndrome?
  • Antisynthetase syndrome
  • AS syndrome
  • Anti-Jo1 syndrome
Who are the top Antisynthetase Syndrome Local Doctors?
Rohit L. Aggarwal
Elite in Antisynthetase Syndrome
Dr. Rohit L. Aggarwal
Rheumatology
Elite in Antisynthetase Syndrome
Dr. Rohit L. Aggarwal
Rheumatology

UPMC Arthritis And Autoimmunity Center

3601 Fifth Ave, Suite 2B, 
Pittsburgh, PA 
Recognized by The Myositis Association
412-647-6700
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Rohit Aggarwal is a Rheumatologist in Pittsburgh, Pennsylvania. Dr. Aggarwal and is rated as an Elite provider by MediFind in the treatment of Antisynthetase Syndrome. His top areas of expertise are Myositis, Dermatomyositis, Polymyositis, and Antisynthetase Syndrome.

Miguel A. Gay-Gonzalez
Elite in Antisynthetase Syndrome
Miguel A. Gay-Gonzalez
Elite in Antisynthetase Syndrome
Miguel A. Gay-Gonzalez
Rheumatology Div, 
Santander And Univ. Of The Witwatersrand, ZA 

Miguel Gay-Gonzalez practices in Santander And Univ. Of The Witwatersrand, South Africa. Mr. Gay-Gonzalez and is rated as an Elite expert by MediFind in the treatment of Antisynthetase Syndrome. His top areas of expertise are Vasculitis, Temporal Arteritis, Giant Cell Arteritis (GCA), Lung Transplant, and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Ingrid E. Lundberg
Elite in Antisynthetase Syndrome
Ingrid E. Lundberg
Rheumatology
Elite in Antisynthetase Syndrome
Ingrid E. Lundberg
Rheumatology
Solna, AB, SE 
Recognized by The Myositis Association

Ingrid Lundberg is a Rheumatologist in Solna, Sweden. Ms. Lundberg and is rated as an Elite expert by MediFind in the treatment of Antisynthetase Syndrome. Her top areas of expertise are Polymyositis, Dermatomyositis, Myositis, and Inclusion Body Myositis.

View All Doctors
What are the latest Antisynthetase Syndrome Clinical Trials?
An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Biological
Study Phase: Early Phase 1

Summary: A single-center, open-label dose-escalation design to evaluate the safety and efficacy of 3 infusions of anti CD19 CAR NK cells (KN5501), as well as the expansion and persistence of KN5501 in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA); To evaluate the ability of KN5501 to clear CD19-positive B cells in patients to determine the feasibility of KN5...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
Enrollment Status: Recruiting
Publish Date: April 03, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2/Phase 3

Summary: This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatm...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center